FLOX-0-FLOX TAB is a potent fixed-dose combination tablet containing 200 mg Ofloxacin and 500 mg Ornidazole, engineered for the effective treatment of mixed bacterial and protozoal infections. This dual-action antimicrobial formulation delivers a comprehensive therapeutic approach, targeting infections particularly within the gastrointestinal tract, genitourinary system, and respiratory tract. Ofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase and topoisomerase IV enzymes, effectively blocking bacterial DNA replication and promoting bacterial cell death. Ornidazole, belonging to the nitroimidazole class, specifically targets anaerobic bacteria and protozoa by disrupting DNA synthesis through its metabolic activation within anaerobic pathogens. Manufactured under the Dr Precision label by BluepillExpress in WHO-GMP certified facilities, FLOX-0-FLOX TAB assures impeccable quality, consistency, and regulatory compliance, making it suitable for global B2B pharmaceutical supply chains. Ideal for treating acute diarrheal diseases, amoebiasis, giardiasis, bacterial vaginosis, pelvic inflammatory disease, urinary tract infections, post-surgical infections, and anaerobic respiratory infections, this combination reduces the treatment complexity by offering broad-spectrum coverage in a single tablet. The formulation supports improved patient compliance and rapid clinical recovery, streamlining antimicrobial therapy in hospitals and community healthcare settings worldwide.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | 200 mg Ofloxacin and 500 mg Ornidazole per tablet |
| Therapeutic Spectrum | Broad-spectrum antibacterial and antiprotozoal activity |
| Targeted Infections | Gastrointestinal, genitourinary, respiratory tract infections, and anaerobic bacterial infections |
| Mechanism of Action | Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV; Ornidazole disrupts DNA synthesis in anaerobic bacteria and protozoa |
| Manufacturing Standards | Produced under Dr Precision label in WHO-GMP certified facilities |
| Regulatory Support | Available with full regulatory and private label support for worldwide distribution |
| Dosage Form | Oral fixed dose combination tablet |
| Indications | Acute diarrhea, amoebiasis, giardiasis, bacterial vaginosis, PID, UTIs, post-surgical infections, dental infections, respiratory infections |
| Synergistic Effect | Effective against mixed aerobic and anaerobic infections |
| Provider | Developed and exported by BluepillExpress, a leader in third-party pharmaceutical manufacturing |
| Attributes | Description |
|---|---|
| Dosage Strength | Ofloxacin 200 mg + Ornidazole 500 mg |
| Formulation Type | Fixed-dose combination tablet |
| Pharmacological Classes | Fluoroquinolone antibiotic and Nitroimidazole antiprotozoal/antibacterial |
| Packaging | Available in blister packs or bottles as per client requirement |
| Shelf Life | Minimum 24 months from manufacturing date |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Manufacturing Facility | WHO-GMP certified manufacturing plant under Dr Precision label |
| Regulatory Compliance | Compliant with international pharmaceutical quality and safety standards |
| Application | Hospital and community healthcare settings |
| Distribution Support | Full regulatory and private label services |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
FLOX-0-FLOX TAB is designed to treat a range of bacterial and protozoal infections, including gastrointestinal infections like acute diarrhea, amoebiasis, giardiasis, genitourinary infections such as bacterial vaginosis and urinary tract infections, pelvic inflammatory disease, post-surgical infections, dental infections, and respiratory tract infections that require anaerobic coverage.
Ofloxacin targets aerobic bacteria by inhibiting DNA gyrase and topoisomerase IV enzymes, thereby blocking bacterial DNA replication. Ornidazole acts specifically on anaerobic bacteria and protozoa, disrupting their DNA synthesis through metabolic activation within anaerobic cells. This complementary mechanism provides broad-spectrum coverage against both aerobic and anaerobic pathogens in a single tablet.
Yes, FLOX-0-FLOX TAB is widely used in both hospital and community healthcare settings due to its broad spectrum of activity, ensuring effective treatment of mixed infections without requiring multiple medications.
FLOX-0-FLOX TAB is manufactured under the Dr Precision label in WHO-GMP certified facilities, ensuring strict compliance with international pharmaceutical quality and safety standards.
Yes, BluepillExpress offers full regulatory assistance and private label services for FLOX-0-FLOX TAB, facilitating worldwide pharmaceutical distribution for business partners.
FLOX-0-FLOX TAB should be stored in a cool, dry place, away from direct sunlight to preserve stability and ensure maximum shelf life.
Country Of Origin: India
FLOX-0-FLOX TAB is a fixed-dose combination of Ofloxacin (200 mg) and Ornidazole (500 mg), used to treat a wide spectrum of bacterial and protozoal infections, particularly those affecting the gastrointestinal tract, genitourinary system, and respiratory tract. This dual-action formula offers broad antimicrobial coverage, ensuring rapid symptom relief and improved patient compliance. Manufactured by BluepillExpress, a global leader in third-party pharma manufacturing, this product is offered with full regulatory and private label support for worldwide distribution.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
FLOX-0-FLOX TAB is a high-efficacy combination antimicrobial formulation consisting of Ofloxacin, a fluoroquinolone antibiotic, and Ornidazole, a nitroimidazole class antiprotozoal and antibacterial agent. This synergistic combination is ideal for mixed infections involving anaerobic bacteria and protozoa, especially in regions where such dual-pathogen infections are common.
Developed and exported by BluepillExpress, this formulation is manufactured in WHO-GMP certified facilities under strict international quality controls. It is widely used in both hospital and community settings for treating gastrointestinal infections, dysentery, bacterial vaginosis, post-operative infections, and gynecological infections.
Therapeutic Indications
Acute diarrheal conditions with suspected bacterial and protozoal causes
Amoebiasis and Giardiasis
Bacterial vaginosis and mixed vaginal infections
Pelvic inflammatory disease (PID)
Urinary tract infections (UTIs)
Post-surgical infections of the abdomen and pelvis
Dental infections and periodontal infections
Respiratory tract infections where anaerobic coverage is needed
Mechanism of Action
Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to the prevention of DNA replication and bacterial death.
Ornidazole enters anaerobic cells and protozoa, where it undergoes reduction to active metabolites that disrupt DNA synthesis, causing cell death.
This combination ensures a broad-spectrum action covering both aerobic and anaerobic bacteria as well as protozoa, reducing the need for multiple drugs.
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
